Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

Authors

Frederick Dewey•Alanna Morrison•Alan Shuldiner

Published

March 2, 2016

Abstract

Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.